Jubilant, Wistar Institute to Develop COVID-19 Therapy

Pennsylvania-based Jubilant Therapeutics and Philadelphia’s Wistar Institute are collaborating on a treatment that could tamp down the out-of-control immune reactions that occur in some COVID-19 patients.

The collaborators will assess the company’s peptidyl arginine deiminase 4 (PAD4) inhibitors for their ability to prevent the potentially fatal immune reactions.

Beyond COVID-19 and other viral infections, PAD4 inhibitors also show potential for treating autoimmune disorders, such as rheumatoid arthritis, the company said.